Gonapeptyl (Triptorelin Acetate)

Gonapeptyl is indicated for several hormone‑dependent conditions where suppression of sex hormone production is desired.

• Treatment of advanced prostate cancer in men.
• Management of endometriosis‑associated pain.
• Reduction of uterine fibroid size and related symptoms.
• Control of central precocious puberty in children.
• Use in assisted reproductive technology protocols for controlled ovarian stimulation.

Side effects reported with Gonapeptyl vary in frequency and severity.

Common

• Hot flashes, sweating, or transient feeling of warmth.
• Headache, which may be mild to moderate in intensity.
• Pain, redness, or swelling at the injection site.

Serious

• Severe allergic reaction (anaphylaxis) presenting with rash, swelling, or breathing difficulty.
• Cardiovascular events such as myocardial infarction or stroke, particularly in patients with pre‑existing risk factors.
• Decrease in bone mineral density that may increase fracture risk with long‑term therapy.

Before initiating Gonapeptyl therapy, clinicians should evaluate several precautionary factors to ensure safe use.

• Assess cardiovascular history, as GnRH agonists may exacerbate existing heart disease.
• Evaluate bone health; prolonged treatment can reduce bone mineral density.
• Review endocrine status, especially in patients with diabetes or thyroid disorders.
• Consider potential flare effect, a temporary increase in hormone levels during the first weeks of treatment.
• Monitor liver and renal function, particularly in patients with hepatic or renal impairment.
• Use caution in pregnancy or breastfeeding; the drug may affect fetal development.

Gonapeptyl can interact with other medicines, influencing its effectiveness or safety profile.

Avoid

• Concomitant use with other GnRH agonists or antagonists, which may lead to unpredictable hormone suppression.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that could reduce triptorelin plasma levels.

Use with caution

• Hormone replacement therapies, as they may counteract the intended hormone suppression.
• Anticoagulants, because injection site bleeding may be prolonged.
• Chemotherapeutic agents, requiring coordinated scheduling to avoid overlapping toxicities.